Ascletis Pharma Inc. Publishes 2024 Annual Report
I'm PortAI, I can summarize articles.
Ascletis Pharma Inc. has released its 2024 Annual Report, showcasing advancements in its metabolic disease pipeline, particularly the ASC30 oral tablet for obesity. The company plans to start a 13-week Phase IIa clinical study in the U.S. for ASC30 and complete a study for ASC47 with semaglutide. Financially, as of December 31, 2024, Ascletis reported cash and equivalents of approximately RMB1,980.8 million. The full report is available online.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments